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ABSTRACT: Many neurodegenerative diseases are associated
with the self-assembly of peptides and proteins into fibrillar
aggregates. Soluble misfolded oligomers formed during the
aggregation process, or released by mature fibrils, play a relevant
role in neurodegenerative processes through their interactions with
neuronal membranes. However, the determinants of the
cytotoxicity of these oligomers are still unclear. Here we used
liposomes and toxic and nontoxic oligomers formed by the same
protein to measure quantitatively the affinity of the two oligomeric
species for lipid membranes. To this aim, we quantified the
perturbation to the lipid membranes caused by the two oligomers by using the fluorescence quenching of two probes embedded in
the polar and apolar regions of the lipid membranes and a well-defined protein−oligomer binding assay using fluorescently labeled
oligomers to determine the Stern−Volmer and dissociation constants, respectively. With both approaches, we found that the toxic
oligomers have a membrane affinity 20−25 times higher than that of nontoxic oligomers. Circular dichroism, intrinsic fluorescence,
and FRET indicated that neither oligomer type changes its structure upon membrane interaction. Using liposomes enriched with
trodusquemine, a potential small molecule drug known to penetrate lipid membranes and make them refractory to toxic oligomers,
we found that the membrane affinity of the oligomers was remarkably lower. At protective concentrations of the small molecule, the
binding of the oligomers to the lipid membranes was fully prevented. Furthermore, the affinity of the toxic oligomers for the lipid
membranes was found to increase and slightly decrease with GM1 ganglioside and cholesterol content, respectively, indicating that
physicochemical properties of lipid membranes modulate their affinity for misfolded oligomeric species.
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■ INTRODUCTION
Many neurodegenerative diseases, including Alzheimer’s
disease (AD), Parkinson’s disease (PD), Creutzfeld-Jacob
disease (CJD), Huntington disease (HD), frontotemporal
dementia (FTD), familial amyloid polyneuropathy (FAP), and
many others are associated with the self-assembly of specific
peptides or proteins into misfolded fibrillar aggregates known
as amyloid fibrils.1,2 The formation of amyloid fibrils is a
generic characteristic of proteins, and it is also found for a large
number of systems that are not associated with disease.3−5
Multiple lines of evidence suggest that small soluble oligomers
formed in the process of amyloid fibril formation or released by
mature fibrils are important players of the neurotoxicity
associated with protein aggregation.1,6−10 These species have
an ability to bind to and destabilize biological membranes,
inducing an entry of Ca2+ from the extracellular space into the
cytosol. This phenomenon seems to be generic, as it has been
found for oligomers of the amyloid β peptide,11−13 α-
synuclein,9,14 islet-amyloid polypeptide,15 calcitonin,16,17 as
well as model oligomers.11,18,19
The study of the structural elements of misfolded protein
oligomers responsible for neuronal dysfunction and of the
mechanism through which they cause neurotoxicity has
benefited from the isolation of pairs of oligomers of the
same protein having a toxic and benign effect, respec-
tively.18−23 One of such pairs is that obtained from the 91-
residue N-terminal domain of [NiFe]-hydrogenase maturation
factor HypF (HypF-N) from E. coli.18,19 Oligomer formation
of HypF-N can be readily and reproducibly directed into two
morphologically similar forms, previously named type A
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(toxic) and type B (nontoxic) oligomers (OAs and OBs,
respectively), by altering the solution conditions. Although this
protein domain has no known link to human disease, it has
proved to be a valuable model system as its toxic OAs have
been shown to have effects indistinguishable from those of
Aβ42 oligomers associated with AD at the biochemical,
electrophysiological and animal model levels.11,18,19,24−29
OAs manifest a strong ability to bind and penetrate the lipid
bilayer of cell membranes.18,19,30 This interaction induces a
series of downstream events associated with cytotoxicity,
including an influx of calcium ions (Ca2+) from the cell
medium to the cytoplasm, generation of intracellular reactive
oxygen species (ROS), lipid peroxidation, perforation of cell
membranes with exit of intracellularly trapped large molecules,
caspase-3 activation, and mitochondrial damage.18,19 OAs also
induce loss of cholinergic neurons when microinjected into rat
brains with an associated impairment of spatial memory in rats,
colocalization with synapses in primary neurons, and inhibition
of long-term potentiation (LTP) in rat hippocampal slices.19,26
By contrast, OBs were found to bind to lipid membranes on
the surface, without infiltrating their lipid bilayer, and were not
found to have any of the deleterious biological effects observed
for OAs.18,19,26
A recent interactome approach to detect all the membrane
proteins of microglia N13 cells interacting with OAs and OBs
showed that OBs had a higher affinity for membrane proteins
relative to OAs.31 By contrast, other experiments with
supported lipid bilayers (SLBs) devoid of proteins treated
with OAs and OBs and monitored with atomic force
microscopy (AFM) revealed that numerous OAs were bound
strongly with both the gel and liquid-disordered phases of
SLBs, whereas few OBs were found to have this ability.30 It was
therefore concluded that although both species bind to cell
membranes, only OAs bind to, penetrate, and cross the lipid
bilayer of the membranes, thus manifesting their toxic
behavior.30,31 In particular, the GM1 concentration depend-
ence of the OA toxicity in cell cultures and of OA binding to
SLBs showed that the oligomers binding to the gel-phase (Lβ
or So) of the lipid bilayer are responsible for the OA toxicity.
30
In terms of their morphology and structure, both oligomer
types were found to be highly stable, spheroidal, or discoidal
under atomic force microscopy (AFM) with a diameter of 2−6
nm, to possess a similar β-sheet core structure, and to display
weak thioflavin T (Th-T) binding.18,32,33 In spite of these
structural similarities, characterization of these species at a
molecular level revealed important differences.18,32 By labeling
the oligomers with pyrene at various sequence positions, it was
shown that nontoxic OBs are stabilized by intermolecular
interactions between the three major hydrophobic regions of
the sequence, such that a lower fraction of the hydrophobic
residues are solvent-exposed on the oligomer surface relative to
the toxic OA species.18 Such interactions are weaker in the
toxic oligomers so that a larger fraction of hydrophobic
residues are solvent exposed.18 The binding of the fluorescent
reporter 8-anilinonaphthalene-1-sulfonic acid (ANS) was also
found to be higher in OAs, confirming a higher exposure of
hydrophobic clusters.18 Solution-state and solid-state nuclear
magnetic resonance (NMR) spectroscopy and site-directed
fluorescence resonance energy transfer (FRET) experiments,
involving residues labeled with a donor and acceptor at various
positions, showed that toxic OAs have a greater compactness
and structural rigidity, so that structural constraints are
generated that cause a number of the hydrophobic residues
to interact less strongly with each other, with a fraction of them
becoming exposed to the solvent.32 Accordingly, FRET
efficiency values were, on average, higher in toxic OAs than
nontoxic OB species, except when donor and acceptor labeling
involved hydrophobic residues, when the opposite situation
was observed.32
The binding of OAs to the bilayer of cell membranes
represents an important event in the mechanism through
which these oligomeric species manifest their toxicity to
neuroblastoma cells and primary neurons.11,18,19 However,
given the complexity of cellular systems, methods for
quantitative measurements of oligomer-membrane binding,
for example, in terms of association or dissociation constants,
are not well established. In addition, it is not clear whether the
oligomers change their structures upon interacting with cell
membranes. To address these issues, we have used liposomes
in the form of large unilamellar vesicles (LUVs) with a variable
and biologically compatible lipid composition and OAs/OBs of
HypF-N. Our results indicate that OAs are characterized by a
higher and measurable affinity than OBs for the LUV bilayer
and that the native protein does not bind to the lipid
membranes. We also found that neither oligomer type changes
its structure upon interaction with the LUVs and that OAs do
not feature a preferential binding to any of the lipids contained
in LUVs. We then reveal quantitatively the effects of
trodusquemine, a promising and previously studied small
molecule that binds to the membrane, on the OA−membrane
affinity and on the mechanism of displacement of these toxic
oligomers from the bilayer and, again in a quantitative manner,
how the lipid composition of LUVs can influence the affinity of
toxic oligomers for the membranes.
■ RESULTS AND DISCUSSION
The Binding Affinity of OAs to LUVs is 20−25 Times
Higher than That of OBs. Toxic OAs and nontoxic OBs
were preformed from purified HypF-N at a total concentration
of 0.5 mg/mL, corresponding to 48 μM (monomer
equivalents), as previously reported.18,33 LUVs were prepared
using DOPC and SM in a molar ratio of 2:1 (mol/mol), 1%
(mol) CHOL and 1% (mol) GM1, as previously reported.34
LUVs were prepared at various mass concentrations (mg/mL);
at a total lipid concentration of 1 mg/mL, for example, molar
concentrations were 836 μM DOPC, 418 μM SM, 13 μM
CHOL and 13 μM GM1.
We first checked whether OAs and OBs bound to LUVs. To
this purpose, we formed separately supported lipid bilayers
(SLBs) with the same lipid composition as LUVs, treated them
with 12 μM OAs or 12 μM OBs (monomer equivalents), and
then imaged them with AFM. The images show that OAs bind
to the gel-phase domains (Lβ or So) and to the liquid-
disordered phase (Lα or Ld) of the SLBs with 1% GM1,
whereas only few OBs were found to be bound to them
(Figure S1), in agreement with previous results obtained with
5% GM1 as the only difference in LUV composition relative to
our LUV preparations.30 Furthermore, the difference in the
thickness between the Lβ and Lα domains (ΔZ) is altered by
the presence of OAs, but not OBs, clearly indicating the
presence of structural changes of the overall bilayer (Table S1),
again in agreement with the result obtained with 5% GM1.30
In order to obtain a more quantitative measure of the
binding affinity of the OAs and OBs for lipid membranes, we
evaluated the ability of these oligomers to quench DPH and its
derivative TMA-DPH, two fluorescent probes that incorporate
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within the hydrophobic region35 and polar head region36 of the
lipid bilayer, respectively. The 15 min incubation of increasing
concentrations of OAs (from 0 to 32.5 μM monomer
equivalents) with TMA-DPH- and DPH-labeled LUVs (0.3
mg/mL, 384 μM total lipids) caused a marked and
concentration-dependent reduction of the fluorescence emis-
sion of both fluorescent probes, with a more consistent
quenching of TMA-DPH (Figure 1A,B). The KSV constant is a
measure of the quenching of the dye fluorescence operated by
the oligomers and obtained by fitting the data to eq 4 (see
Materials and Methods) and is also a measure of the affinity of
the oligomers for the membrane-embedded probe, as it reports
on the collisions between OAs and the probe.37 The KSV value
was found to be 48.2 ± 2.0 mM−1 for TMA-DPH and 14.5 ±
1.7 mM−1 for DPH (Figure 1). The incubation of OBs with
TMA-DPH- and DPH-labeled LUVs under identical con-
ditions caused a significantly weaker fluorescence quenching
(Figures 1A,B and S2A,B), with KSV values of 3.7 ± 0.7 and 2.2
± 0.4 mM−1, respectively, which reflected a lower binding to
the membrane and the absence of lipid membrane alteration
(Figure 1). Native HypF-N showed a substantially absent
ability to quench both TMA-DPH and DPH (Figures 1A,B
and S2A,B), with KSV values of 1.2 ± 1.1 mM
−1 and 1.6 ± 0.4
mM−1, respectively, reflecting the absence of binding to the
membrane (Figure 1). By subtracting these two background
values from the corresponding ones obtained for OAs and
OBs, one can determine that OAs have KSV values ca. 20-fold
higher than OBs with both probes.
To obtain an independent measure of the binding affinity of
the three HypF-N species for the LUV membrane, we labeled
HypF-N with BODIPY FL and then prepared samples of OAs,
OBs and native proteins using the labeled and unlabeled
protein at a molar ratio of 1:10. The 15 min incubation of
native HypF-N (20 μM) with increasing concentrations of
unlabeled LUVs (0−2.0 mg/mL, 0−2.6 mM total lipids)
caused a weak decrease of protein fluorescence that was found
to correlate linearly with LUV concentration (Figure 1C). A
similar decrease, even with the same slope, was observed for
the highly soluble reduced glutathione (GSH) labeled with
BODIPY FL (Figure S3), indicating that it consists of a LUV-
induced fluorescence drift, most probably arising from light
scattering as the LUV concentration increases. The 15 min
incubation of OAs (20 μM monomer equivalents) with
increasing concentrations of unlabeled LUVs (0−2.0 mg/mL,
0−2.6 mM) caused a marked decrease of OA fluorescence
from 0 to ca. 0.4 mg/mL LUVs (corresponding to 0.5 mM
total lipids), followed by the same drift at higher LUV
concentrations (Figure 1C). By fitting the data points to a
binding function (eq 6), we obtained a dissociation constant
(KD) value of 0.09 ± 0.04 mg/mL, corresponding to 0.12 ±
0.05 mM of total lipids, indicating binding of OAs to the LUV
bilayer. The fluorescence of OBs also decreased significantly
with LUV concentration, to an extent lower relative to that of
OAs, but larger relative to native HypF-N or GSH (Figure
1C), indicating real binding. The fitting of the data points to eq
6 led to a KD value of ca. 2.5 mg/mL, corresponding to ca. 3.2
mM of total lipids, indicating an affinity for LUVs lower, by ca.
25-fold, relative to OAs.
Hence, under the conditions used here, we have quantified
the binding affinity of toxic OAs and nontoxic OBs of a sample
protein for the bilayer of lipid vesicles (LUVs) by measuring
the KSV values of fluorescence quenching of membrane-
embedded TMA-DPH and DPH caused the oligomers (0.3
mg/mL LUVs or 384 μM total lipids) and the oligomer-
membrane KD values (20 μM protein in monomer
equivalents). Although KSV
−1 has been shown to correspond
Figure 1. Binding of OAs/OBs/native HypF-N to LUVs. (A,B) Stern−Volmer plots reporting the ratio of fluorescence of TMA-DPH (A) and
DPH (B) in 0.3 mg/mL LUVs in the absence (F0) or presence (F) of various concentrations (monomer equivalents) of OAs (red circles), OBs
(blue triangles), and native HypF-N (green squares). The straight lines through the data points represent the best fits to eq 4. (C) Binding plots
reporting the fluorescence at 512 nm of 20 μM BODIPY-FL-labeled OAs (red circles), OBs (blue triangles), and native HypF-N (green squares)
versus LUV concentration reported in mg/mL units (bottom x axis) or mM units (top x axis). The lines through the data points represent the best
fits to eq 6. (D,E) Bar plots reporting the KSV values obtained from TMA-DPH (D) and DPH (E) fluorescence quenching using eq 4. (F) Bar plots
reporting the KD values from binding using eq 6. Experimental errors represent SEM of 2−5 experiments. The symbols * and *** refer to p values
of <0.1 and <0.001, respectively, relative to KSV values of the native protein (D,E) and relative to the KD value of OAs (F).
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to KD,
37 these values are not immediately comparable in our
system because they were measured in different conditions,
that is at constant LUV concentration (0.3 mg/mL) upon
varying OA concentration and at constant OA concentration
(20 μM), upon varying that of LUVs, respectively. The
molarities of KSV
−1 and KD also refer to protein and total lipids,
respectively, and are not, therefore, comparable. In both cases,
however, the binding affinity of the toxic OAs for the
membrane appears to be ca. 20−25 times higher than nontoxic
OBs. Albeit with much lower affinity, nontoxic OBs also bind
to the LUV membrane, unlike the native protein.
Can we relate the data obtained here with LUVs to cell
cultures and brain tissues? By using a mean diameter of 7.5 ±
0.5 μm known for human neuroblastoma SH-SY5Y cells,38 a
lipid density of a membrane bilayer estimated from LUVs of
425 ± 3 ng/cm2,34 and a cell density value of neuroblastoma
SH-SY5Y cells commonly used to test the toxicity of OA/OB
species of ca. 7.5(±0.7) 104 cells/cm2,29 and then extrapolating
this value to the three-dimensional space, one can determine a
lipid concentration of 0.06 ± 0.01 mg/mL in SH-SY5Y cell
cultures where OA/OB species are tested. The KD value of
0.09 ± 0.04 mg/mL lipids measured here for OAs, and referred
to total lipid concentration, implies that a significant fraction of
OAs (40 ± 15%) are bound to the lipid membranes of cells, as
soon as the equilibrium between membrane-bound and
membrane-unbound OAs is established and before they
enter into the cells. By contrast, the KD value of ∼2.5 mg/
mL lipids measured for OBs, implies that a very minor fraction
of OB species interact with the cell membrane (∼2%).
The Binding to LUVs Does Not Detectably Affect the
Structures of OAs and OBs. One of the questions that is
often raised when studying the structure−toxicity relationship
of misfolded protein oligomers is whether the structural
characteristics determined for the oligomers in aqueous
suspension are maintained or changed upon the interaction
with biological membranes. Difficulties to address this issue
arise from interferences by cellular or membrane proteins that
make it very difficult to monitor the structural characteristics of
the oligomers with conventional spectroscopic probes. Here
we circumvented this problem using protein-free LUVs and
three optical probes to which LUVs are spectroscopically
silent, making it possible to monitor the secondary and tertiary
structure of the oligomers before and after their binding to the
membrane.
We first acquired far-UV CD and intrinsic fluorescence
spectra of OAs, OBs and native HypF-N incubated with
increasing concentrations of LUVs. The far-UV CD spectra of
OAs, OBs, and native HypF-N (20 μM monomer equivalents)
were not found to be significantly different in the absence or
presence of the various LUV concentrations (0−1.5 mg/mL),
indicating that their secondary structure was maintained upon
interaction with LUVs (Figure 2A−C). The intrinsic
tryptophan fluorescence spectra of the three species (1.9 μM
monomer equivalents) were also similar in the absence or
presence of the various LUV concentrations (0−1.5 mg/mL)
in terms of wavelength of maximum fluorescence and overall
shape, featuring only a linear intensity decrease as the LUV
concentration increases, again attributable to light scattering
caused by LUVs, as explained above. This indicates that the
presence of LUVs did not influence the chemical environment
around the tryptophan residues of the protein (Figure 2D−F).
In addition, we performed experiments of intraoligomer
FRET in the presence of increasing concentrations of LUVs.
Two HypF-N mutants having only one cysteine residue at
Figure 2. Far-UV CD and intrinsic fluorescence spectra of OAs, OBs, and native HypF-N. (A−C) Far UV CD spectra of OAs (A), OBs (B), and
native HypF-N (C) in the presence of increasing concentrations of LUVs. Spectra were blank-subtracted and normalized using eq 1. (D−F)
Intrinsic tryptophan fluorescence emission spectra of OAs (D), OBs (E), and native HypF-N (F) in the presence of increasing concentrations of
LUVs.
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positions 18 and 34 were labeled with the donor dye 1,5-
IAEDANS and the acceptor dye 6-IAF, respectively, and then
mixed in a 1:1 molar ratio to form OAs and OBs to a final
protein concentration of 20 μM monomer equivalents. The
FRET E values determined by analyzing the resulting
fluorescence spectra acquired following 10 min-incubation
with unlabeled LUVs (0−0.7 mg/mL) were not found to
significantly change when varying LUV concentration, either
for OAs or for OBs (Figure 3). This result indicates that the
mean shortest donor−acceptor distance in the oligomers does
not change upon LUV addition and suggests that the
intermolecular structure of the oligomers was not significantly
altered by the presence of LUVs.
The OA-LUV Binding Does Not Involve Specific Lipid
Species. Since only OAs were found to have a high affinity for
LUVs, we continued our study with this species. In order to
investigate whether the binding between LUVs and OAs could
depend on a specific interaction with one of the lipids
contained in LUVs, we performed FRET experiments using 20
μM (monomer equivalents) OAs labeled with 1,5-IAEDANS
as a donor probe (OA-D) and 0.3 mg/mL LUVs containing
one of the four lipids labeled with BODIPY-FL as an acceptor
probe (Lipid-A). These experiments were carried out
separately by using each of four lipids contained in the
LUVs labeled with A. The FRET E values were obtained by the
analysis of the fluorescence spectra acquired after 15 min
(Figure 4A) and were found to be 0.18 ± 0.04 for OA-D/
GM1-A, 0.27 ± 0.05 for OA-D/CHOL-A, 0.23 ± 0.09 for OA-
D/SM-A and 0.15 ± 0.03 for OA-D/DOPC-A, without
significant differences between the various FRET pairs
examined (Figure 4B).
This analysis indicates that OAs bind to LUVs but do not
have a preferential interaction with any of the four lipids.
Therefore, the role played by GM1 in the oligomer−
membrane interaction, observed here and previously,11,30,39
involves a change of the bilayer physical properties, without a
direct preferential interaction of the lipid with the oligomers.
Indeed, it is clear that GM1 increases the overall negative net
charge of the membrane,34 increases the thickness of the
membrane, particularly of the Lβ phase,
30,40 and decreases
lateral diffusion,41 all known to contribute to a facilitated
oligomer insertion.
Trodusquemine Reduces the Binding Affinity of OAs
for LUVs. We then investigated whether trodusquemine
(Figure S4), which has been reported to displace toxic
oligomers from lipid membranes,27,42,43 could induce a
variation of the affinity of OAs for the membrane, as measured
with TMA-DPH and DPH fluorescence quenching and OA
fluorescence change upon LUV binding. To this aim, we
prepared TMA-DPH and DPH-labeled LUVs (0.3 mg/mL,
384 μM total lipids) containing 5 μM trodusquemine, and we
incubated them with increasing concentrations of unlabeled
OAs (0−32.5 μM monomer equivalents). Previous experi-
ments have shown that trodusquemine has a high affinity for
LUVs of this type and partitions completely in the bilayer at
this concentration.34 The presence of trodusquemine in the
bilayer caused a significant reduction of the TMA-DPH
fluorescence quenching, with an almost complete absence of
quenching at low concentrations of OAs up to ca. 10 μM
(Figure 5A). At higher concentrations of OAs, the TMA-DPH
quenching was evident, but remained lower than that observed
in the absence of trodusquemine at corresponding OA
concentrations, showing a reduction of the affinity of OAs
for LUVs (Figure 5A). A similar profile was observed by
repeating the experiment with DPH-labeled LUVs (Figures 5B
and S2C).
Figure 3. Intraoligomer FRET between OAs and OBs LUVs. (A,B)
Fluorescence emission spectra of OAs (A) and OBs (B) formed by
18D_10 (green), 10_34A (red), and 18D+34A (blue), obtained in
the presence of increasing concentrations of LUVs (0.12, 0.3, 0.5, and
0.7 mg/mL). (C) FRET E values of OAs (gray) and OBs (black) in
the presence of increasing concentrations of LUVs, determined using
eq 2. Experimental errors are SD.
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Interestingly, the absence of TMA-DPH and DPH
fluorescence quenching at the concentrations of OAs that
normally cause dysfunction and toxicity to cell cultures (<10
μM monomer equivalents) and at the concentration of
trodusquemine that causes protection (5 μM) indicates that
this small molecule provides protection by preventing OA-
LUV binding. By contrast, at higher OA concentrations, the
oligomer-displacing effect of the molecule is overcome, most
probably because in the excess of OAs trodusquemine
partitions to OAs more markedly27 and populates the
membrane to a lower extent. However, under these excess
OA concentrations and in the presence of 5 μM
trodusquemine, the KSV constant remains lower than that
observed in the absence of the small molecule. This
phenomenon indicates that at the toxic OA concentrations
and protective trodusquemine concentrations the molecule is
largely effective as a protective factor but partly loses its
protective action in the presence of excess oligomers.
We then incubated BODIPY FL-OAs (20 μM) with
increasing concentrations of unlabeled LUVs (0−2.0 mg/mL,
0−2.6 mM total lipids) containing the same molar fraction of
trodusquemine, and we repeated the analysis described above
in the absence of the small molecule, but this time with the
molecule (Figure 5C). Trodusquemine was found to
significantly increase the KD, from a value of 0.09 ± 0.04
mg/mL in its absence (corresponding to 0.12 ± 0.05 mM
lipids) to a value of 0.86 ± 0.65 mg/mL in its presence
(corresponding to 1.10 ± 0.83 mM lipids), therefore reducing
the binding affinity of OAs to LUVs by 1 order of magnitude
(Figure 5C). Using the same arguments described above to
translate these data into a cell culture context, under these
conditions of analysis trodusquemine induces a decrease of
membrane-bound OAs from ∼40% in the absence of the
molecule to ∼6% in its presence. Numerical values of KSV and
KD with and without trodusquemine are reported in Figure
5D−F.
Change of OA-LUV Binding Affinity with LUV
Composition. It is increasingly clear that membrane lipids
have a crucial role in the binding of misfolded protein
oligomers to the bilayer,44−46 particularly GM1 and
CHOL.11,39,47−49 In order to better mimic the physiological
content of GM1 and CHOL in neuronal plasma membranes,
and in light of the fact that the content of these two lipids plays
a crucial role in the interaction with LUVs and toxicity of
misfolded protein oligomers,11,39,44,47−50 we decided to explore
whether the variation of these two lipids in LUVs could affect
the affinity of OAs for LUVs (Figure 6). To this aim, we
performed the TMA-DPH quenching experiment with OAs
and LUVs with 0%, 0.5%, 1%, and 5% (molar fractions) GM1
(Figure 6A). In the absence of GM1, OAs showed a
significantly reduced affinity for the membrane of LUVs (KSV
value of 34.7 ± 2.0 mM−1), which was then found to increase
with GM1 content (KSV value up to 49.2 ± 0.4 mM
−1 with 5%
GM1), confirming the crucial role of this lipid in the
membrane-oligomer interaction (Figure 6A,C). We then
changed the CHOL content and performed the TMA-DPH
quenching experiment with OAs and LUVs with 0%, 1%, 5%,
and 10% (molar fractions) CHOL (Figure 6B). In this case, we
observed a small decrease in the KSV parameter (Figure 6B,D).
Since trodusquemine was found to preferentially bind to
GM1 and CHOL in LUVs,34 we repeated the TMA-DPH
quenching experiment using LUVs containing trodusquemine
and various contents of GM1 and CHOL, in order to
investigate whether the reduction of the KSV induced by this
aminosterol could be affected by the lipid composition of
LUVs. Trodusquemine induced a significant reduction of the
TMA-DPH fluorescence quenching at all GM1 and CHOL
concentrations, with an almost complete protection from
quenching at low OA concentration, and an evident quenching
at higher concentration of OAs, but still lower than the
corresponding values in the absence of the aminosterol (Figure
6). In the presence of trodusquemine, the KSV value in the
linear portion of the plot was found to increase with GM1
content and to slightly decrease with CHOL content,
confirming the relationships observed in the absence of the
small molecule (Figure 6C,D).
In conclusion, we have investigated quantitatively one of the
main mechanisms by which toxic oligomers commonly
associated with neurodegenerative diseases can exert cytotoxic
effects, namely their aberrant interactions with lipid mem-
branes. The results indicate that the toxicity of the oligomers
depends on their ability to bind stably the lipid membranes,
whereas nontoxic oligomers have 20−25 times reduced affinity,
and native proteins do not have this action (Figure 7A−C).
Correspondingly, we have also found that changes in the
composition of the lipid membranes themselves, including
Figure 4. FRET between OAs labeleld with donor (D) and the
various lipids labeled with acceptor (A) contained in LUVs. (A)
Fluorescence emission spectra of OA-D+Lipid-A (blue), OA-D
(green), and Lipid-A (red). (B) FRET E values of the indicated
FRET pairs examined, obtained using eq 3. Experimental errors
represent SEM of 5 experiments.
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those induced pharmacologically, can decrease the affinity of
the toxic oligomers for the lipid membranes (Figure 7D−F).
These results therefore offer insight on one of the fundamental
molecular mechanisms of cellular degeneration caused by
misfolded protein oligomers and suggest pharmacological
approaches to increase the resistance of the cells to this type
of insult.
■ MATERIALS AND METHODS
Expression and Purification of Wild-Type and Mutant forms
of HypF-N. Cultures of E. coli XL10 Gold harboring the pQE30-Th
plasmids for the expression of wild-type HypF-N and its mutational
variants18 were grown overnight at 37 °C under shaking in 200 mL of
20 g/L LB medium (Sigma-Aldrich, St. Louis, MO, USA) containing
100 μg/mL of ampicillin (Sigma-Aldrich). The cells were then diluted
1:20 in 4 l of fresh medium and grown at 25 °C under shaking until
∼0.6 optical density at 600 nm (OD600), monitored with a Jasco V-
630 UV−vis spectrophotometer (Tokyo, Japan). Protein expression
was induced overnight at 25 °C under shaking by the addition of 1
mM isopropyl β-D-thiogalactopyranoside (IPTG, Thermo Scientific,
Waltham, MA, USA). The bacterial cells were then harvested by
centrifugation for 15 min at 7000g at 4 °C; the pellet was resuspended
in ∼30 mL of lysis buffer (50 mM phosphate buffer, 300 mM NaCl,
10 mM imidazole, pH 8.0) and stored at −20 °C overnight. The cell
suspension was defrosted at 37 °C in a Thermo Haake C25P water
bath (Karlsruhe, Germany) and then incubated for 1 h with 1 mg/mL
lysozyme (Sigma-Aldrich) in ice under shaking followed by five cycles
of sonication at 50 kHz for 30 s alternated to 30 s in ice. The cell
lysate was then centrifuged for 45 min at 38 700g at 4 °C and the
supernatant containing the protein was filtered using filters with a
cutoff of 0.45 μM. The filtered supernatant was applied to an affinity
chromatography column packed with HIS-Select Nickel Affinity Gel
(Sigma-Aldrich), previously equilibrated with the lysis buffer at 4 °C.
The column was then washed with the washing buffer (50 mM
phosphate buffer, 300 mM NaCl, 20 mM imidazole, pH 8.0),
equilibrated with the cutting buffer (50 mM phosphate buffer, 50 mM
NaCl, pH 8.0), incubated with 50 units of human thrombin (Sigma-
Aldrich) dissolved in 5 mL of cutting buffer for 1 h at 37 °C, and then
incubated overnight at 4 °C under slight shaking. The pure wild-type
and mutated HypF-N were then eluted using 50 mM phosphate
buffer, 50 mM NaCl, 10 mM imidazole, pH 8.0. Wild-type and
mutant HypF-N were then buffer-exchanged and concentrated in 5
mM acetate buffer, 2 mM dithiothreitol (DTT), pH 5.5, and in 20
mM phosphate buffer, 2 mM tris(2-carboxyethyl)phosphine hydro-
chloride (TCEP), pH 7.0, respectively, using an ultrafiltration cell
with a 3000 Da molecular weight cutoff (MWCO) cellulose
membrane (Biorad, Hercules, CA, USA) at 4 °C. The final solution
containing the pure protein was centrifuged for 10 min at 16 100g to
eliminate any aggregates and/or impurities, and its concentration was
measured with a Jasco V-630 UV−vis spectrophotometer using ε280 =
12490 M−1cm−1. Samples were checked for their purity with SDS-
PAGE and DLS, as described below, and then stored at −80 °C until
use.
SDS-PAGE Analysis of HypF-N. Samples of the various HypF-N
purification steps were denatured with a 4× sample buffer (0.25 M
Figure 5. Interaction of OAs with LUVs with and without trodusquemine. (A,B) Stern−Volmer plots reporting the ratio of fluorescence of TMA-
DPH (A) and DPH (B) in the absence (F0) or presence (F) of various concentrations (monomer equivalents) of OAs, in the absence (red circles)
and presence (black diamonds) of 5 μM trodusquemine (TRO) in 0.3 mg/mL LUVs. The straight lines through the data points represent the best
fits to eq 4 (red line) and eq 5 (black line). Experimental errors represent SEM of 2−5 experiments. (C) Binding plots reporting the fluorescence at
512 nm of OAs in the absence (red circles) and presence (black diamonds) of TRO in LUVs, versus LUV concentration. The lines through the
data points represent the best fits to eq 6. (D,E) Bar plots reporting the KSV values obtained from TMA-DPH (D) and DPH (E) fluorescence
quenching in the absence (red) and presence (black) of 5 μM trodusquemine. (F) Bar plots reporting the KD values obtained from the binding
experiments of OAs in the absence (red) and presence (black) of 5 μM trodusquemine. Experimental errors represent SEM of 2−5 experiments.
The symbols *** refer to p values of <0.001 relative to KSV (D,E) and KD (F) values of OAs in the absence of trodusquemine.
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Tris, 5.4 M glycerol, 0.3 M β-mercaptoethanol, 277 mM SDS, 6 mM
bromophenol blue) and then incubated at 98 °C for 2 min. The
resulting samples and a molecular weight marker (Precision Plus
Protein Standard, Bio-Rad Laboratories, Hercules, CA, USA) were
loaded in a precast gel with a gradient of 4−20% of acrylamide (Mini-
PROTEAN TGX Precast Gels, Biorad) and then run for about 90
min at 20 mA, using the Bio-Rad Laboratories electrophoresis kit
(Hercules, CA, USA). The running chambers were filled with a
running buffer (25 mM Tris, 19.2 mM glycine, 0.1% SDS). The gel
was then stained with Coomassie Blue dye (40% methanol, 10%
acetic acid, 0.1% Coomassie Blue) for 30 min at 37 °C with slow
agitation and then washed in a destaining solution (40% methanol,
10% acetic acid) for at least 1 h at room temperature to remove the
excess of dye. The purified protein featured a single band at 10 kDa, in
agreement with its expected molecular weight of 10 464 Da.
DLS Analysis of HypF-N. The monomeric state of purified HypF-
N was assessed acquiring its size distribution on a Zetasizer Nano S
DLS device from Malvern Panalytical (Malvern, Worcestershire, UK),
thermostated at 25 °C with a Peltier temperature controller and using
a 10 mm reduced-volume plastic cell. The refractive index and
viscosity were 1.33 and 0.89 cP, respectively. The measurement was
acquired with the cell position 4.65, attenuator index 8, at 25 °C. The
DLS distribution in volume mode featured a single population with a
hydrodynamic diameter of 5.4 ± 1.0 nm, which is compatible with a
monomeric folded HypF-N, as determined with X-ray crystallog-
raphy.51
Labeling of HypF-N Mutant with BODIPY FL. The C7S/C65A
mutant of HypF-N (containing only Cys40) was diluted to a final
concentration of 150 μM in 20 mM phosphate buffer, pH 7.0, and
incubated with 2.25 mM BODIPY FL N-(2-aminoethyl)maleimide,
previously dissolved at high concentration in dimethyl sulfoxide
(DMSO) for 2 h at 25 °C in the dark on a mechanical shaker. The
labeled sample was dialyzed (membrane MWCO of 3500 Da) in the
dark against 1.5 l of 20 mM phosphate buffer, pH 7.0, overnight and
then centrifuged to remove any precipitate. The concentration of the
dye in the BODIPY FL-labeled HypF-N mutant was determined
spectrophotometrically, using ε505 = 76 000 M
−1 cm−1, whereas the
concentration of the protein was determined using ε280 = 12490
M−1cm−1. The labeling degree of the sample was then estimated by
Figure 6. Binding of OAs to LUVs with various lipid compositions. (A,B) Stern−Volmer plots reporting the ratio of fluorescence of TMA-DPH in
the absence (F0) or presence (F) of various concentrations (monomer equivalents) of OAs, in the absence (various shades of red circles), and in
the presence (various shades of gray diamonds) of 5 μM trodusquemine (TRO) in 0.3 mg/mL LUVs containing different percentage of GM1 (A)
and CHOL (B). The straight lines through the data points represent the best fits to eq 4 (various shades of red lines) and eq 5 (various shades of
gray lines). (C,D) Bar plots reporting the KSV values obtained from TMA-DPH fluorescence quenching in LUVs containing different percentages of
GM1 (C) and CHOL (D) in the absence (various shades of red) and in the presence (various shades of gray) of 5 μM trodusquemine.
Experimental errors represent SEM of 2−5 experiments. The symbols ** and *** refer to p values of <0.01 and <0.001, respectively, relative to KSV
values of OAs without GM1 (C) and without CHOL (D) in the absence of trodusquemine; $ and $$$ refer to p values of <0.05 and <0.001,
respectively, relative to KSV values of OAs without GM1 (C) and CHOL (D) in the presence of trodusquemine.
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determining the ratio between the measured dye and protein molar
concentrations.
Labeling of HypF-N Mutants with 1,5-IAEDANS and 6-IAF.
The C7S/C40S/C65A/Q18C (named C18) and C7S/C40S/C65A/
N34C (named C34) mutants of HypF-N (containing one cysteine
residue at position 18 and 34, respectively) were labeled with 5-((((2-
iodoacetyl)amino)ethyl)amino)naphthalene-1-sulfonic acid (1,5-IAE-
DANS) and 6-iodoacetamidofluorescein (6-IAF) dyes (Thermo
Fisher Scientific, Waltham, MA, USA), respectively, as previously
reported.32 The C18 variant was diluted to a final concentration of
180 μM in 100 mM potassium phosphate buffer, pH 7.0, with 2.7 mM
1,5-IAEDANS (15-fold molar excess of dye) and 3 M guanidine
hydrochloride (GdnHCl), whereas the C34 variant was diluted to the
same final concentration of 180 μM in 100 mM potassium phosphate
buffer, pH 7.0, with 1.8 mM 6-IAF (10-fold molar excess of dye) and
3 M GdnHCl. Both dyes were previously dissolved in dimethylfor-
mamide (DMF) at high concentration. The two labeling mixtures
were left in the dark under shaking for 2 h at 30 °C and then
overnight at 4 °C. They were then dialyzed in the dark (membrane
MWCO of 3000 Da) against: (i) 0.25 L of 100 mM potassium
phosphate buffer, pH 7.0, with 1.5 M GdnHCl for 4 h, (ii) 0.25 L of
100 mM potassium phosphate buffer, pH 7.0 for 4 h, (iii) 0.5 L of 50
mM potassium phosphate buffer, pH 7.0, overnight, and (iv) 1.0 L of
20 mM or 5 mM potassium phosphate buffer (depending on whether
the labeled mutants were used to produce type A or type B oligomers,
respectively), at pH 7.0, for 6 h. The samples were then centrifuged to
remove any precipitate. The concentrations of the dye in the 1,5-
IAEDANS-C18 variant and in the 6-IAF-C34 variant were determined
spectrophotometrically, using ε336 = 5700 and ε491 = 8200 M
−1 cm−1,
respectively. The protein concentration was determined spectropho-
tometrically using ε280 = 12 490 M
−1 cm−1 after subtraction of the
absorbance contribution of the 1,5-IAEDANS/6-IAF probe at the
same wavelength of 280 nm. The labeling degree was estimated as the
ratio between the two measured dye and protein molar concen-
trations.
Preparation of HypF-N OAs and OBs. OAs and OBs of wild-
type HypF-N were obtained at a protein concentration of 0.5 mg/mL,
corresponding to 48 μM (monomer equivalents), by incubating the
Figure 7. Summary of the results obtained in this work about the affinity of OAs and OBs for LUV lipid membranes. (A−C) Schematic
representation of the affinity of the native protein (green, no affinity) (A), OBs (blue, low affinity) (B), and OAs (red, high affinity) (C) for the
LUV lipid membrane. (D−F) Change of the OAs affinity due to the addition of trodusquemine (decreased affinity) (D), increase of GM1
concentration (increased affinity) (E), and increase of CHOL concentration (slightly decreased affinity) (F) in LUVs.
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protein for 4 h at 25 °C in (i) 50 mM acetate buffer, 12% (v/v)
trifluoroethanol (TFE), 2 mM DTT, pH 5.5 and (ii) 20 mM
trifluoroacetic acid (TFA), 330 mM NaCl, pH 1.7, respectively, as
previously described.18
BODIPY FL-labeled OAs and OBs used for the binding
experiments were obtained under the same conditions, but using
4.4 μM of BODIPY FL-labeled C7S/C65A HypF-N and 43.6 μM of
unlabeled C7S/C65A HypF-N, in order to obtain a 1:10 molar ratio
for labeled/unlabeled protein.
OAs and OBs for intraoligomer FRET were formed under the same
conditions by 24 μM C18 variant labeled with the donor dye 1,5-
IAEDANS (18D) and 24 μM C34 variant labeled with the acceptor
dye 6-IAF (34A), at a molar ratio 18D:34A of 1:1. These oligomers
were named 18D_34A. Oligomers 18D_10 and 10_34A (with 34A
and 18D replaced by the unlabeled HypF-N mutant with only one
cysteine residue at position 10, respectively) were also produced in a
1:1 molar ratio between labeled and unlabeled variant.
OAs and OBs for LUV-oligomer FRET were initially formed under
the same conditions using C7S/C65A HypF-N. They were then
centrifuged at 16,100 g for 15 min at 20 °C. The supernatants were
removed, the pellets were gently dried with nitrogen flow and then
resuspended in 20 mM phosphate buffer, 2 mM TCEP, pH 7.0, to a
final HypF-N concentration (monomer equivalents) of 160 μM. They
were then incubated with a 12.5-fold molar excess of 1,5-IAEDANS,
previously dissolved at high concentration in DMF for 2 h at 25 °C in
the dark on a mechanical shaker. The labeled samples were dialyzed
(membrane MWCO of 3500 Da) in the dark against 1.5 l of 20 mM
phosphate buffer, pH 7.0, overnight and then centrifuged to remove
any precipitate. The concentration of the dye in the samples was
determined spectrophotometrically, using and ε336 = 5700 M
−1 cm−1,
whereas the concentration of the protein was determined using ε280 =
12 490 M−1 cm−1 after subtraction of the absorbance contribution of
1,5-IAEDANS at 280 nm. The labeling degree was estimated as the
ratio between the measured dye and protein molar concentrations.
Preparation of LUVs. LUVs were prepared using DOPC and SM
in a molar ratio of 2:1 (mol/mol), 1% (mol) CHOL and 1% (mol)
GM1, as previously reported.34 These lipid species are known to be
present in the neuronal membranes.50,52−54 The non-natural
percentages of the various lipids were chosen to favor well-separated
Lβ domains and Lα regions.
55 In particular, the CHOL percentage of
1% was already adopted in other works30,34,55−58 and it is necessary to
obtain model membranes with well distinct Lα and Lβ phases and
relatively extended Lβ domains. It was demonstrated that the Lβ
domains significantly decreased their size by increasing the CHOL
concentration, becoming indistinguishable for microscopic analyses.55
The ordered domains of LUVs, enriched in GM1 and CHOL,
partially mimic the complex features of lipid rafts in neurons.50,59
Moreover, the progressive increase of CHOL and GM1 content in our
experiments, aim at better mimicking the real composition of
neuronal membranes.
LUVs were obtained by dissolving the desired lipid mixture in
chloroform/methanol (2:1) and by removing the organic solvent by
evaporation in vacuo (Univapo 150H, UniEquip, Munich, Germany)
for 3 h. The mixtures were hydrated with distilled water to form
multilamellar vesicles (MLVs) to a total lipid concentration of 2 mg/
mL for quenching experiments, 3.5 mg/mL for binding experiments, 1
mg/mL for LUV-oligomer FRET experiments, and 3 mg/mL for
circular dichroism (CD), tryptophan fluorescence and intraoligomer
FRET experiments (mother solutions). MLVs were left to swell for 1
h at 60 °C and then extruded 17 times through a polycarbonate
membrane with 100 nm pores using a mini-extruder (Avanti Polar
Lipids) at the same temperature, to form LUVs. After cooling to room
temperature, LUVs were stored at 4 °C for a maximum of 1 week.
The lipid mixtures were: (i) 1,2-dioleoyl-sn-glycero-3-phosphocoline
(DOPC, Avanti Polar Lipids, Alabaster, AL, USA) and sphingomyelin
(SM, Sigma-Aldrich, Darmstadt, Germany) in a molar ratio of 2:1
(mol/mol), 1% (mol) cholesterol (CHOL, Sigma-Aldrich) and 1%
(mol) monosialotetrahexosylganglioside 1 (GM1, Avanti Polar
Lipids); (ii) DOPC and SM in a molar ratio of 2:1 (mol/mol), 1%
(mol) CHOL; (iii) DOPC and SM in a molar ratio of 2:1 (mol/mol),
1% (mol) CHOL and 5% (mol) GM1; (iv) DOPC and SM in a molar
ratio of 2:1 (mol/mol) and 1% (mol) GM1; (v) DOPC and SM in a
molar ratio of 2:1 (mol/mol), 5% (mol) CHOL and 1% (mol) GM1;
(vi) DOPC and SM in a molar ratio of 2:1 (mol/mol), 10% (mol)
CHOL and 1% (mol) GM1. LUVs containing trodusquemine were
obtained by adding the aminosterol during the hydration phase to
obtain final trodusquemine and total lipid concentrations of 5 μM and
0.3 mg/mL, respectively.
Interaction between OAs/OBs and SLBs Using AFM. The
interaction was tested on SLBs with three different lipid mixtures: (i)
DOPC/SM 2:1 (mol/mol), 1% (mol) CHOL; (ii) DOPC/SM 2:1
(mol/mol), 1% (mol) CHOL, 1% (mol) GM1; (iii) DOPC/SM 2:1
(mol/mol), 1% (mol) CHOL, 5% (mol) GM1. Aliquots (40 μL) of
LUV suspensions (0.1 mg/mL) were deposited onto a 1.0 × 1.0 cm2
freshly cleaved mica substrate with 10 μL of a 10 mM CaCl2 solution.
The samples were kept for 15 min at room temperature and then
incubated for 15 min at 60 °C in a close chamber with 100% relative
humidity to form a uniform SLB. Subsequently, the samples were
cooled at room temperature and gently rinsed three times with Milli-
Q water. A Nanowizard III (JPK Instruments, Germany) mounted on
an Axio Observer D1 (Carl Zeiss, Germany) inverted optical
microscope was used to acquire the AFM images. V-shaped DNP
silicon nitride cantilevers (Bruker, MA, USA), with a typical tip
curvature radius of 20−60 nm, nominal spring constant 0.24 N/m,
and a resonance frequency in air ranging from 40 kHz to 75 kHz were
used. The measurements were carried out in water using the
intermittent contact mode in the constant-amplitude mode, working
with an oscillating frequency of 10−20 kHz. The amplitude set point
was kept above 70% of free oscillation amplitude in all cases. OAs and
OBs were administered under the AFM head at a final concentration
of 12 μM and left standing to interact with the SLBs for 30 min. AFM
images (512 × 512 image data points) were processed using the JPK
Data Processing software (JPK Instruments, Germany). The differ-
ence in thickness (ΔZ) between gel (Lβ) and fluid (Lα) lipid domains
was determined by considering image height distributions. The
distributions were fitted to the sum of two Gaussian functions, and
the ΔZ value was determined as the difference between the peaks of
the two Gaussian functions. This procedure was repeated for at least
10 different images for each experiment.
Intrinsic Tryptophan Fluorescence Assay. OAs, OBs, and
native HypF-N were diluted in 20 mM phosphate buffer, pH 7.0, in
the presence of different concentrations of LUVs (0, 0.04, 0.08, 0.12,
0.24, 0.30, 0.50, 1.00, 1.50 mg/mL) to a final HypF-N concentration
(monomer equivalents) of 1.9 μM (OAs and OBs) and 20 μM (native
HypF-N) for 15 min at 25 °C. DLS was used to assess the integrity of
LUVs upon change of solution conditions from distilled water (in
which they were prepared) to 20 mM phosphate buffer, pH 7.0. The
structural integrity of OAs and OBs upon change of solution
conditions was assessed previously.18 Intrinsic tryptophan fluores-
cence spectra were then acquired at 25 °C from 300 to 450 nm
(excitation at 280 nm) using a 3 mm × 3 mm black wall quartz cell on
a PerkinElmer LS 55 spectrofluorimeter (Wellesley, MA, USA)
equipped with a thermostated cell-holder attached to a Haake F8
water-bath (Karlsruhe, Germany), or on an Agilent Cary Eclipse
spectrofluorimeter (Agilent Technologies, Santa Clara, CA, USA)
equipped with a thermostated cell holder attached to a Agilent PCB
1500 water Peltier system.
Far Ultraviolet (Far-UV) CD. OAs, OBs and native HypF-N were
diluted in 20 mM phosphate buffer, pH 7.0, in the presence of
different concentrations of LUVs (0, 0.04, 0.08, 0.12, 0.24, 0.30, 0.50,
1.00, 1.50 mg/mL), to a final HypF-N concentration (monomer
equivalents) of 20 μM for 10 min at 25 °C. The far-UV CD spectra
were collected over the 190−260 nm wavelength range at 25 °C using
a using a 1 mm path length cell on a Jasco J-810 spectropolarimeter
(Tokyo, Japan) equipped with a thermostated cell holder attached to
a Thermo Haake C25P water bath (Karlsruhe, Germany). All spectra
were truncated at HT > 700 V, blank-subtracted and normalized to
mean residue ellipticity using
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θ θ[ ] =
× × ×( )N10 residues optical path concentrationmolecular weight (1)
where [θ] is the mean residue ellipticity in deg cm2 dmol−1, θ is the
ellipticity in mdeg, optical path is in cm, concentration is in g/l, and
molecular weight is in g/mol.
Intraoligomer FRET. OAs and OBs (18D_34A, 18D_10 and
10_34A) formed at a total monomer concentration of 48 μM were
diluted in 20 mM and 5 mM potassium phosphate buffer (for OAs
and OBs, respectively), pH 7.0, to obtain a final HypF-N
concentration (monomer equivalents) of 20 μM, and in the presence
of different concentrations of LUVs (0.12, 0.3, 0.5, and 0.7 mg/mL)
prepared as described above. Oligomers and LUVs were incubated for
10 min at 25 °C. The samples were diluted to a final HypF-N
concentration of 2 μM immediately before fluorescence acquisition.
Fluorescence emission spectra were recorded on a PerkinElmer LS55
spectrofluorimeter (Wellesley, MA, USA) equipped with a thermo-
stated cell-holder attached to a Haake F8 water-bath (Karlsruhe,
Germany). The measurements were performed using a 2 mm × 10
mm quartz cell at 25 °C with excitation at 336 nm. The FRET
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where AA and AD represent the absorbance values at 336 nm of
acceptor (AA = 0.05) and donor (AD = 0.07), respectively, obtained in
the presence of a concentration of dye of 120 μM; FDA and FA
represent the acceptor fluorescence emission at 1 mM (excitation 336
nm) obtained in the presence and in the absence of donor,
respectively, determined from the area between 490 and 600 nm
below the corresponding curves.32
LUVs-Oligomers FRET. LUVs were prepared at a total lipid
concentration of 1 mg/mL, as described above, in the presence of
either BODIPY-FL C5-ganglioside GM1 (GM1-A, commercial name
BODIPY-FL C5-Ganglioside GM1, ThermoFisher Scientific), BOD-
IPY-FL cholesterol (CHOL-A, commercial name TopFluor choles-
terol, Avanti Polar Lipids), BODIPY-FL-sphingomyelin (SM-A,
commercial name TopFluor Sphingomyelin, Avanti Polar Lipids) or
BODIPY-FL-DOPC (DOPC-A, commercial name TopFluor PC,
Avanti Polar Lipids) used as acceptors, with a molar fraction of each
labeled lipid of 1% relative to total lipids in all cases. OAs from the
C7S/C65A mutant labeled on their surface with 1,5-IAEDANS were
prepared at a total protein concentration of 160 μM, as described
above, and used as donor (OA-D). Fluorescence spectra of 0.3 mg/
mL nonlabeled LUVs incubated with 20 μM OA-D (OA-D spectra),
0.3 mg/mL LUVs containing lipid-A incubated with 20 μM
nonlabeled OAs (Lipid-A spectra), and 0.3 mg/mL LUVs containing
lipid-A incubated with 20 μM OA-D (OA-D+Lipid-A spectra) were
acquired after 15 min of incubation on a PerkinElmer LS 55
spectrofluorimeter equipped with a thermostated cell-holder attached
to a Haake F8 water bath. The spectra were acquired from 350 to 600
nm using a 3 × 3 mm black wall quartz cell at 25 °C, with excitation at












where FDA is the fluorescence intensity of D in the presence of A and
FD is the fluorescence intensity of D in the absence of A.
Fluorescence Quenching of DPH and TMA-DPH in LUVs.
1,6-Diphenyl-1,3,5-hexatriene (DPH, Sigma-Aldrich) and 1-(4-
trimethylammoniumphenyl)-6-phenyl-1,3,5-hexatriene p-toluenesul-
fonate (TMA-DPH, ThermoFisher scientific) were dissolved in
chloroform/methanol (2:1) and added to the lipid mixture to obtain
a probe:lipid molar ratio of 1:300. LUVs were then prepared at 2 mg/
mL as described above, diluted with distilled water to 0.3 mg/mL and
incubated with increasing concentrations of OAs, OBs, and native
protein (0 to 32.5 μM) at 25 °C for 15 min in the dark. The
fluorescence spectra of the resulting samples were acquired at 25 °C
from 380 to 550 nm (excitation 355 nm) using a 3 mm × 3 mm black
walls quartz cell on an Agilent Cary Eclipse spectrofluorimeter
(Agilent Technologies, Santa Clara, CA, USA) equipped with a
thermostated cell holder attached to an Agilent PCB 1500 water
Peltier system. The quenching of TMA-DPH and DPH was then
analyzed with the Stern−Volmer equation
= + × [ ]
F
F
K Q10 SV (4)
where F0 and F are the integrated fluorescence intensity areas at 400−
500 nm in the absence and presence of the quencher (OAs, OBs, or
native proteins), respectively; [Q] is the concentration of the
quencher and KSV is the Stern−Volmer constant. The plot of
quenching of TMA-DPH and DPH in 0.3 mg/mL LUVs containing 5
μM trodusquemine was analyzed from 12.5 μM OAs with an equation
derived from the Stern−Volmer equation
= + × [ ]
F
F
q K Q0 SV (5)
where q is the intercept and all the other parameters have the same
meaning as in eq 4.
Binding Assay of OAs, OBs and Native Proteins to LUVs.
OAs, OBs and native HypF-N formed by BODIPY FL-labeled and
unlabeled HypF-N C7S/C65A mutant (molar ratio 1:10) were
diluted in 20 mM phosphate buffer, pH 7.0, to obtain a final HypF-N
mutant concentration of 20 μM (monomer equivalents), and were
incubated for 15 min at 25 °C, with increasing concentrations (from 0
to 2.0 mg/mL) of LUVs prepared as described above. In experiments
involving trodusquemine-containing LUVs, the concentration of the
small molecule was variable but the trodusquemine/lipid molar ratio
was maintained and corresponded to 5 μM in 0.3 mg/mL LUVs. The
fluorescence spectra were acquired at 25 °C from 490 to 560 nm
(excitation 480 nm) using a 3 mm × 3 mm black walls quartz cell on
the Agilent Cary Eclipse spectrofluorimeter described above. The
fluorescence emission at 512 nm was then plotted versus LUV
concentration and analyzed with
= [ ] × + [ ] − − ×
[ ] × [ ]
+ [ ]
F f m f f
K
OA lipid ( )
OA lipid
lipidU U B D
(6)
where F is the observed fluorescence at 512 nm, [OA] is the molar
concentration of OAs (monomer equivalents), f U and f B are the
fluorescence emission of the unbound and bound OAs at unitary
concentration of OAs, respectively, m is the dependence of F on
[lipid] after binding (drift), [lipid] is the molar concentration of total
lipids in LUVs, and KD is the dissociation constant.
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